Biogen beats estimates on cost cuts and new drugs like leqmbi, but right outlook falls shorts

Biogen On Wednsday Posted Fourth-Quarter Revenue and Profit that Topped Expectations as it Cost Cuts Showed Progress and new productsIncluding its breakthrough alzheimer’s treatment LeqmbiSaw growth.

But the biotech company’s guidance for the current year Missed Wall Street’s Expectations. Biogen Issued a full-year 2025 adjusted earnings outlook of $ 15.25 to $ 16.25 per share, which fell short of the $ 16.34 per share that analysts, accouaking to lseg. That reflects a foreign exchange headwind of 35 cents per share, biogen said.

Biogen expects revenue to decline by a “Mid-hangle digit” Percentage in 2025 compared with 2024, as sales of its Multiple Sclerosis Products Fall. That portion of the business has declined For Several Quarters as some of that therapies face generic competition.

But Biogen Expects Leqmbi, Along with its new rare disease and depression treatments, to help offset that sliding revanue this year.

Lequembi generated $ 87 million in revealed for the fourth quality, Including $ 50 million in the us analysts had expected the drug to book $ 67 million in sales, according to estimate.

Leqmbi, which biogen shares with the japanese drugmaker EisaiBecame the second drug proven to slow the program of alzheimer’s to win approval in the us in 2023. The therapy’s launch has been given gradual due to bottlenecks related to diagnostic test requirements, Need for Regular Brain Scans and the Difability of Finding Neurologists, Among Other Issues.

Here’s what biogen reported for the fourth quarter compared with what wall street was expecting, based on a survey of analysts by lseg:

• Earnings per share: $ 3.44 adjusted vs. $ 3.35 per share expected
• Revenue: $ 2.46 billion vs. $ 2.40 billion expected

Bioogen Booked Sales of $ 2.46 Billion for the Quarter, which is up Around 3% from the year-aarlier period.

The Drugmaker Posted Net Income of $ 266.8 Million, or $ 1.83 per share, for the Quarter. That compares with network of $ 249.7 Million, or $ 1.71 per share, for the same period a year ago.

Adjusting for one-time items, include results restructuring charges and costs associated with intangible assets, the company reported earnings of $ 3.44 per share.

Biogen first initiated a cost-cutting program in 2023. The company expects to generate $ 1 billion in gross savings, or $ 800 million nets, by the end of 2025.

Also on Wednsday, Royalty Pharma Announced An Agreement to Provide $ 250 Million in Research and Development Funding to Biogen for Litifilimab, A Key Drug in Its Pipeline that is being studged to tree Lupus. Royalty Pharma, a Leading Funder of the Biotech and Pharmaceutical Industry, will be eligible for regulatory milstones and certain royalties.